By Fineline Cube Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that it has initiated a Phase I clinical study of LAE118 for the treatment of advanced solid tumors in China and completed the first patient dosing. LAE118 is a novel, highly potent PI3Kα pan-mutant-selective inhibitor independently developed by Laekna — and a validated asset on the global stage, after US rare disease drug company Vasque Bio acquired its global development and commercialization rights for up to USD 527 million in June 2026.
Development Milestone
| Item | Detail |
|---|---|
| Sponsor | Laekna (HKG: 2105) |
| Candidate | LAE118 (novel PI3Kα pan-mutant-selective inhibitor) |
| Indication | Advanced solid tumors |
| Event | Phase I study initiated in China; first patient dosed |
| Announcement Date | 01 Sep 2026 |
| Licensing | Global development and commercialization rights acquired by Vasque Bio for up to USD 527 million (June 2026) |
Drug Profile & Mechanism of Action
- Molecule: LAE118, a novel, highly potent inhibitor independently developed by Laekna
- Mechanism: Selective inhibition of pan-mutant PI3Kα — designed to target oncogenic PIK3CA mutations broadly while sparing wild-type PI3Kα, a key driver of on-target toxicity (hyperglycemia) in earlier-generation PI3K inhibitors
- Indication: Advanced solid tumors, a setting where PIK3CA mutations are prevalent across multiple cancer types
- Differentiation: Pan-mutant selectivity aims to widen the therapeutic window versus prior PI3Kα inhibitors, potentially improving both tolerability and clinical utility
- External Validation: The June 2026 deal with Vasque Bio — up to USD 527 million for global rights — provides third-party valuation of the asset ahead of clinical readouts
Market Impact & Outlook
- Clinical De-Risking Begins: First-patient dosing moves LAE118 into first-in-human testing, where safety, pharmacokinetics, and early efficacy signals will set the tone for the program
- PI3Kα Next-Generation Race: Pan-mutant-selective PI3Kα inhibitors represent a sought-after next wave in targeted oncology, with selectivity positioned to overcome the tolerability limits that constrained earlier drugs in the class
- License-Backed Economics: With global rights held by Vasque Bio, Laekna‘s upside is framed by milestone and royalty economics from the up-to-USD 527 million agreement, reducing its own development capital burden
- China Execution: Laekna retains a domestic Phase I program in China, keeping local development optionality alongside the global partnership
- Catalyst Watch: Phase I safety/PK readouts and Vasque Bio‘s plans for global development will be the key value drivers for LAE118
Forward‑Looking Statements — This brief contains forward-looking statements regarding clinical development, licensing arrangements, and market potential that involve risks and uncertainties. Clinical outcomes cannot be guaranteed. Nothing herein constitutes investment advice.-Fineline Info & Tech